Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- ASKA: Competition Cuts Sales, Profits
June 2, 2008
- R&D NEWS IN BRIEF
June 2, 2008
- Toyama Chemical: Geninax Lifts Sales 61.7%
June 2, 2008
- OPINION／Leaders Are Readers
June 2, 2008
- Agreement Rate of Over 70% by End of Sept. Acceptable?
June 2, 2008
- CV Market to Level Off in 2008 after Major NHI Price Revision
June 2, 2008
- No Losses due to Sales Prices Lower than Invoice Prices: Hearings Completed with 20 Wholesalers
June 2, 2008
- Daiichi Sankyo Prepares for Next Leap in FY2008
June 2, 2008
- Makers Should Reconsider Invoice Prices as Market Prices Change: Mr Hamada
June 2, 2008
- STOP PRESS
June 2, 2008
- BUSINESS NEWS IN BRIEF
June 2, 2008
- 8 Top Domestic Companies Report Strong Growth in Overseas Sales, Big Increases in R&D Spending
June 2, 2008
- Bungyo Will Spread through Promotion of the Use of Generics: Mr Mitsuhara
June 2, 2008
- Otsuka: Pharma Sales Up 11.1% to \640.2 Bil.
June 2, 2008
- Individual Doctors Should Be Free to Choose Generics or Original Drugs: Dr Fujiwara of JMA
June 2, 2008
- Ono: Opalmon Pushes Up Sales by 3.0%
June 2, 2008
- Daiichi Sankyo to Acquire U3 Pharma of Germany
June 2, 2008
- Will Generics Take Off? (Final)
June 2, 2008
- Kyorin: Sales Up 5.2% Driven by Good Sales of Kipres
June 2, 2008
- Protosera Cooperates with 5 Firms to Search for Biomarkers
June 2, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…